Mark Erskine Howard
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mark Erskine Howard has a total of 544 co-authors. Here are the top co-authors by number of shared publications:
- Shantha Mw Rajaratnam
Department of Medicine, Harvard Medical School, Boston, Massachusetts, United States
41 shared publications - Melinda L. Jackson
Monash University
31 shared publications - David John Berlowitz
Institute for Breathing and Sleep, Austin Health
24 shared publications - Mark É. Czeisler
Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts, United States
23 shared publications - Charles A. Czeisler
Division of Sleep and Circadian Medicine, Department of Medicine, Mass General Brigham, Boston, USA
19 shared publications Maree Barnes
Institute for Breathing and Sleep, Austin Health , Heidelberg, VIC
16 shared publications
Latest Publications
- Open Access
- 6 October 2026
- Published by Elsevier in Sleep Medicine
- Vol. 149
Obstructive sleep apnoea and Alzheimer's disease pathology: a review of plausible pathological mechanisms and potential modifying impact of hypertension
- 6 October 2026
- Published by Elsevier in Sleep Medicine
- Vol. 149
Open AccessObstructive sleep apnoea and Alzheimer's disease pathology: a review of plausible pathological mechanisms and potential modifying impact of hypertension
- Open Access
- 8 July 2026
- Published by Springer Nature in Sleep and Breathing
- Vol. 30 (4) , 211
Capillary versus arterial blood gases. Accuracy, acceptability, and suitability for use during sleep studies to calibrate transcutaneous carbon dioxide measurement
Purpose: To determine whether capillary blood gas carbon dioxide values can substitute for arterial sampling to calibrate transcutaneous carbon dioxide during polysomnography. Methods: Participants underwent capillary (arterialized earlobe) and blood gas (radial artery) sampling at polysomnography commencement (Evening) and end (Morning). Participant and scientist sample preference, and participant pain were recorded. The transcutaneous offset from the corresponding arterial/capillary sample, and the transcutaneous electrode drift over the night were determined. Results: Seventy-five people consented and 44 had complete paired timepoint data. Both the capillary and arterial carbon dioxide values were higher than the transcutaneous (capillary evening mean -0.9 ± standard deviation 2.8, capillary morning -2.5 ± 3.9, arterial evening -3.7 ± 2.7, arterial morning -5.6 ± 3.8 mmHg). Capillary and arterial measures were comparable for assessing transcutaneous carbon dioxide drift (mean difference -0.3 mmHg (95% confidence interval -1.3, 0.7). The failure rate for both techniques was equivalent. Patients and scientists both preferred the capillary method. Conclusion: Capillary blood gas sampling of carbon dioxide levels from the earlobe is feasible. Capillary sampling provides a comparable measure of transcutaneous carbon dioxide drift, but not absolute offset, during polysomnography to that observed with radial arterial sampling. Importantly, patients prefer the capillary technique as it is less painful.
- 8 July 2026
- Published by Springer Nature in Sleep and Breathing
- Vol. 30 (4) , 211
Open AccessCapillary versus arterial blood gases. Accuracy, acceptability, and suitability for use during sleep studies to calibrate transcutaneous carbon dioxide measurement
Purpose: To determine whether capillary blood gas carbon dioxide values can substitute for arterial sampling to calibrate transcutaneous carbon dioxide during polysomnography. Methods: Participants underwent capillary (arterialized earlobe) and blood gas (radial artery) sampling at polysomnography commencement (Evening) and end (Morning). Participant and scientist sample preference, and participant pain were recorded. The transcutaneous offset from the corresponding arterial/capillary sample, and the transcutaneous electrode drift over the night were determined. Results: Seventy-five people consented and 44 had complete paired timepoint data. Both the capillary and arterial carbon dioxide values were higher than the transcutaneous (capillary evening mean -0.9 ± standard deviation 2.8, capillary morning -2.5 ± 3.9, arterial evening -3.7 ± 2.7, arterial morning -5.6 ± 3.8 mmHg). Capillary and arterial measures were comparable for assessing transcutaneous carbon dioxide drift (mean difference -0.3 mmHg (95% confidence interval -1.3, 0.7). The failure rate for both techniques was equivalent. Patients and scientists both preferred the capillary method. Conclusion: Capillary blood gas sampling of carbon dioxide levels from the earlobe is feasible. Capillary sampling provides a comparable measure of transcutaneous carbon dioxide drift, but not absolute offset, during polysomnography to that observed with radial arterial sampling. Importantly, patients prefer the capillary technique as it is less painful.
- Open Access
Associations between SARS-CoV-2 Infection and Multidimensional Sleep Health
Puhrpose: To evaluate the short- and long-term cross-sectional associations between COVID-19 infection and multidimensional sleep health. Methods: Data from the COVID-19 Outbreak Public Evaluation (COPE) initiative were used to examine the association between a novel multidimensional sleep health measure (COPE Multidimensional Sleep Health Scale, CMSHS) modeled from the RuSATED instrument and (1) COVID-19 infection and (2) post-acute sequelae of SARS-CoV-2 infection (PASC). Results: Data from 11,326 respondents were used for this study. The cohort was comprised of 51% women, 61% non-Hispanic White, and 17% Hispanic adults. COVID-19 infection was more prevalent among participants who had not received a booster vaccination (55.4% vs. 30.2%, p<0.001); the number of comorbid conditions was higher among those who had been infected (2.2% vs. 1.7%, p<0.001). Participants with COVID-19 infection had significantly lower CMSHS scores indicative of worse sleep health compared with uninfected participants (3.52 ± 1.37 vs. 3.78 ± 1.30; p < 0.001). Participants with PASC had lower CMSHS scores in comparison to those without PASC (2.72 ± 1.30 vs. 3.82 ± 1.28, p<0.001). In adjusted models, a progressive decline in CMSHS scores was observed over 12 months following infection (3.52 ± 0.05 vs. 2.98 ± 0.04; p < 0.001 for <1 month vs. 6–12 months). Conclusion: Compared with uninfected individuals, multidimensional sleep health was worse among persons who had a COVID-19 infection. Individuals with PASC had greater and persistent reductions in sleep health for up to 12 months post-infection. Brief summary: Several studies have examined the negative effects of COVID-19 on sleep, however the effects of COVID-19 infection on multidimensional sleep health remain poorly understood as do these associations over time. Using a large, population-based cohort, this study evaluates short- and long-term effects of Covid-19 infection on overall sleep health. The study provides evidence that COVID-19 infection is associated with impairments in overall sleep health, with effects persisting up to 12 months post-infection. The findings in this study demonstrate that poor sleep health is an important long-term consequence of COVID-19 infection and emphasizes the need for sleep assessment among patients affected by COVID-19.
Open AccessAssociations between SARS-CoV-2 Infection and Multidimensional Sleep Health
Puhrpose: To evaluate the short- and long-term cross-sectional associations between COVID-19 infection and multidimensional sleep health. Methods: Data from the COVID-19 Outbreak Public Evaluation (COPE) initiative were used to examine the association between a novel multidimensional sleep health measure (COPE Multidimensional Sleep Health Scale, CMSHS) modeled from the RuSATED instrument and (1) COVID-19 infection and (2) post-acute sequelae of SARS-CoV-2 infection (PASC). Results: Data from 11,326 respondents were used for this study. The cohort was comprised of 51% women, 61% non-Hispanic White, and 17% Hispanic adults. COVID-19 infection was more prevalent among participants who had not received a booster vaccination (55.4% vs. 30.2%, p<0.001); the number of comorbid conditions was higher among those who had been infected (2.2% vs. 1.7%, p<0.001). Participants with COVID-19 infection had significantly lower CMSHS scores indicative of worse sleep health compared with uninfected participants (3.52 ± 1.37 vs. 3.78 ± 1.30; p < 0.001). Participants with PASC had lower CMSHS scores in comparison to those without PASC (2.72 ± 1.30 vs. 3.82 ± 1.28, p<0.001). In adjusted models, a progressive decline in CMSHS scores was observed over 12 months following infection (3.52 ± 0.05 vs. 2.98 ± 0.04; p < 0.001 for <1 month vs. 6–12 months). Conclusion: Compared with uninfected individuals, multidimensional sleep health was worse among persons who had a COVID-19 infection. Individuals with PASC had greater and persistent reductions in sleep health for up to 12 months post-infection. Brief summary: Several studies have examined the negative effects of COVID-19 on sleep, however the effects of COVID-19 infection on multidimensional sleep health remain poorly understood as do these associations over time. Using a large, population-based cohort, this study evaluates short- and long-term effects of Covid-19 infection on overall sleep health. The study provides evidence that COVID-19 infection is associated with impairments in overall sleep health, with effects persisting up to 12 months post-infection. The findings in this study demonstrate that poor sleep health is an important long-term consequence of COVID-19 infection and emphasizes the need for sleep assessment among patients affected by COVID-19.
- Open Access
Evaluating the effectiveness of vestibular and ocular motor function assessments in detecting driver sleepiness: A Protocol Paper
Background: Prolonged wakefulness, restricted sleep, and circadian factors can impact driving performance and road safety. Currently, there are no effective objective roadside tests to detect the state of driver sleepiness during or prior to driving, or predict future driving impairment risk. This paper reports on an extended wakefulness protocol used to determine if a portable virtual reality device to administer vestibular-ocular motor function (VOM) tests can effectively detect 1) driver state of sleepiness during or just prior to driving, and 2) predict trait sleepiness and future driving risk. Methods: Fifty healthy adults with regular sleep within 9pm to 8am were recruited for an experimental laboratory procedure which involved two phases: an initial overnight sleep study, and a subsequent period of extended wakefulness lasting ~29 hours. During the wakefulness phase, participants undertook neurobehavioural testing, a simulated driving test, and repeat assessments of VOM to establish if ocular markers can predict sleepiness state and sleepiness-related performance impairments (Trial registry ACTRN12621001610820). Discussion: This protocol outlined a study that aimed to establish the sensitivity of VOM test the effects of extended wakefulness and circadian phase on driver state and trait sleepiness and subsequent sleepiness-related driving impairment. Furthermore, the protocol aims to define the best VOM predictors to identify driver sleepiness state (road side testing and pre-drive assessments) and sleepiness trait (predicting future driving risk) to establish proof of concept for its potential application as a roadside, pre-drive and general sleepiness related fitness to drive test.
Open AccessEvaluating the effectiveness of vestibular and ocular motor function assessments in detecting driver sleepiness: A Protocol Paper
Background: Prolonged wakefulness, restricted sleep, and circadian factors can impact driving performance and road safety. Currently, there are no effective objective roadside tests to detect the state of driver sleepiness during or prior to driving, or predict future driving impairment risk. This paper reports on an extended wakefulness protocol used to determine if a portable virtual reality device to administer vestibular-ocular motor function (VOM) tests can effectively detect 1) driver state of sleepiness during or just prior to driving, and 2) predict trait sleepiness and future driving risk. Methods: Fifty healthy adults with regular sleep within 9pm to 8am were recruited for an experimental laboratory procedure which involved two phases: an initial overnight sleep study, and a subsequent period of extended wakefulness lasting ~29 hours. During the wakefulness phase, participants undertook neurobehavioural testing, a simulated driving test, and repeat assessments of VOM to establish if ocular markers can predict sleepiness state and sleepiness-related performance impairments (Trial registry ACTRN12621001610820). Discussion: This protocol outlined a study that aimed to establish the sensitivity of VOM test the effects of extended wakefulness and circadian phase on driver state and trait sleepiness and subsequent sleepiness-related driving impairment. Furthermore, the protocol aims to define the best VOM predictors to identify driver sleepiness state (road side testing and pre-drive assessments) and sleepiness trait (predicting future driving risk) to establish proof of concept for its potential application as a roadside, pre-drive and general sleepiness related fitness to drive test.
- Open Access
- 8 January 2026
- Published by Oxford University Press (OUP) in SLEEP Advances
- Vol. 7 (1)
ACCESS-OSA: a randomized controlled trial for accurate, accessible, and cost-effective screening solutions for obstructive sleep apnoea: study protocol
Obstructive sleep apnoea (OSA) is common and burdensome, yet current diagnostic pathways remain costly and often misclassify patients. Single-night polysomnography (PSG), the diagnostic gold standard, fails to capture night-to-night variability in severity, is difficult to access and costly. Emerging technologies enable multi-night in-home evaluation, but robust comparative evidence regarding accuracy and cost-effectiveness is lacking. This study will evaluate (a) the diagnostic accuracy of three multi-night in-home devices versus conventional single night PSG; (b) the patient and signal characteristics that optimize diagnostic performance; and (c) the cost-effectiveness of these pathways for clinical implementation. We will conduct a three-arm randomized diagnostic strategy trial (n = 500) enrolling adults referred for suspected OSA over a recruitment period of several years from July 2025. All participants will undergo both conventional single-night PSG and multi-night assessment with an under-mattress sensor, oximetry ring, and forehead EEG device. Participants will be randomized to one of three diagnostic pathways, determining the order in which sleep physicians interpret test results. Sleep physicians will provide sequential diagnostic decisions at each stage, and a blinded expert panel will determine consensus diagnoses. The primary outcome is diagnostic accuracy of each pathway compared with consensus diagnosis. Secondary outcomes include cost-effectiveness, patient-reported acceptability, clinical confidence, self-reported long-term symptoms, and health and quality of life outcomes over 12 months follow-up. Findings will provide definitive evidence for whether simplified and accessible multi-night testing can improve accuracy and cost-effectiveness of OSA diagnosis in routine care.
- 8 January 2026
- Published by Oxford University Press (OUP) in SLEEP Advances
- Vol. 7 (1)
Open AccessACCESS-OSA: a randomized controlled trial for accurate, accessible, and cost-effective screening solutions for obstructive sleep apnoea: study protocol
Obstructive sleep apnoea (OSA) is common and burdensome, yet current diagnostic pathways remain costly and often misclassify patients. Single-night polysomnography (PSG), the diagnostic gold standard, fails to capture night-to-night variability in severity, is difficult to access and costly. Emerging technologies enable multi-night in-home evaluation, but robust comparative evidence regarding accuracy and cost-effectiveness is lacking. This study will evaluate (a) the diagnostic accuracy of three multi-night in-home devices versus conventional single night PSG; (b) the patient and signal characteristics that optimize diagnostic performance; and (c) the cost-effectiveness of these pathways for clinical implementation. We will conduct a three-arm randomized diagnostic strategy trial (n = 500) enrolling adults referred for suspected OSA over a recruitment period of several years from July 2025. All participants will undergo both conventional single-night PSG and multi-night assessment with an under-mattress sensor, oximetry ring, and forehead EEG device. Participants will be randomized to one of three diagnostic pathways, determining the order in which sleep physicians interpret test results. Sleep physicians will provide sequential diagnostic decisions at each stage, and a blinded expert panel will determine consensus diagnoses. The primary outcome is diagnostic accuracy of each pathway compared with consensus diagnosis. Secondary outcomes include cost-effectiveness, patient-reported acceptability, clinical confidence, self-reported long-term symptoms, and health and quality of life outcomes over 12 months follow-up. Findings will provide definitive evidence for whether simplified and accessible multi-night testing can improve accuracy and cost-effectiveness of OSA diagnosis in routine care.
- Open Access
- 8 December 2025
- Published by Springer Nature in Discover Public Health
- Vol. 22 (1) , 806
Factors associated with seeking and receiving home antiviral therapy during the coronavirus disease 2019 (COVID-19) pandemic
Home antiviral treatment (HAVT: nirmatrelvir/ritonavir [Paxlovid] and molnupiravir [Lagevrio]) for COVID-19 was approved in December 2021 by the U.S. Food
- 8 December 2025
- Published by Springer Nature in Discover Public Health
- Vol. 22 (1) , 806
Open AccessFactors associated with seeking and receiving home antiviral therapy during the coronavirus disease 2019 (COVID-19) pandemic
Home antiviral treatment (HAVT: nirmatrelvir/ritonavir [Paxlovid] and molnupiravir [Lagevrio]) for COVID-19 was approved in December 2021 by the U.S. Food
- 8 December 2025
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Journal of Biomedical and Health Informatics
- Vol. 29 (12) , 8655-8662
Breathing Cycle-Aware Segmentation for Patient-Ventilator Asynchrony Detection
Patient–ventilator asynchrony (PVA) is a significant challenge in mechanical ventilation, affecting approximately 25% of intensive care unit patients and increasing the risk of lung and diaphragm injury. Segmenting breathing cycles from long ventilation waveforms is essential for the reliable detection of PVA events. However, existing segmentation methods present several limitations: manual annotation is time-consuming; fixed-length window and rule-based segmentation methods lack adaptability to varying respiratory patterns; and supervised deep learning (DL) segmentation methods require large amounts of labelled data for training. To address these issues, we propose an unsupervised breathing cycle-aware segmentation method tailored for PVA detection. Leveraging the quasi-periodic nature of ventilation waveforms, the proposed segmentation method integrates frequency-adaptive clustering, periodicity hints validation, and dynamic segmentation to identify breathing cycle boundaries. We evaluate the proposed breathing cycle-aware segmentation method on a real-world dataset from Austin Health, Melbourne, Australia, where it outperforms baseline approaches on five out of six evaluation metrics. Furthermore, classification experiments using two state-of-the-art DL-based classification models confirm that accurate segmentation of breathing cycles enhances PVA detection performance. In the future, the proposed breathing cycle-aware segmentation method could be integrated into ventilation systems to support clinical decision-making and improve patient care.
- 8 December 2025
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Journal of Biomedical and Health Informatics
- Vol. 29 (12) , 8655-8662
Breathing Cycle-Aware Segmentation for Patient-Ventilator Asynchrony Detection
Patient–ventilator asynchrony (PVA) is a significant challenge in mechanical ventilation, affecting approximately 25% of intensive care unit patients and increasing the risk of lung and diaphragm injury. Segmenting breathing cycles from long ventilation waveforms is essential for the reliable detection of PVA events. However, existing segmentation methods present several limitations: manual annotation is time-consuming; fixed-length window and rule-based segmentation methods lack adaptability to varying respiratory patterns; and supervised deep learning (DL) segmentation methods require large amounts of labelled data for training. To address these issues, we propose an unsupervised breathing cycle-aware segmentation method tailored for PVA detection. Leveraging the quasi-periodic nature of ventilation waveforms, the proposed segmentation method integrates frequency-adaptive clustering, periodicity hints validation, and dynamic segmentation to identify breathing cycle boundaries. We evaluate the proposed breathing cycle-aware segmentation method on a real-world dataset from Austin Health, Melbourne, Australia, where it outperforms baseline approaches on five out of six evaluation metrics. Furthermore, classification experiments using two state-of-the-art DL-based classification models confirm that accurate segmentation of breathing cycles enhances PVA detection performance. In the future, the proposed breathing cycle-aware segmentation method could be integrated into ventilation systems to support clinical decision-making and improve patient care.
- Open Access
Association of Prior COVID-19 Infection with Restorative Sleep Quality Using REST-Q Scores: Findings from the COPE Initiative
Objectives The COVID-19 pandemic has disrupted sleep health globally. However, the relationship between prior SARS-CoV-2 infection and subjective restorative sleep, measured using validated instruments, remains underexplored. This study evaluated the association between prior SARS-CoV-2 infection and restorative sleep quality using Restorative Sleep Questionnaire (REST-Q) scores in a large, nationally representative U.S. sample. Methods Data were obtained from the September–October 2022 wave of the COVID-19 Outbreak Public Evaluation (COPE) Initiative, a cross-sectional online survey of 4,982 adults approximating the U.S. population by age, sex, race, and ethnicity. Restorative sleep was measured using the 9-item REST-Q. COVID-19 infection status was self-reported and categorized as never infected, one infection, or ≥ 2 infections. General linear models and ordinal logistic regression assessed associations between infection status and REST-Q scores, adjusting for demographic, socioeconomic, comorbidity, sleep-related, and mental health variables (Patient Health Questionnaire-4). Results Participants with prior COVID-19 infection had significantly lower REST-Q scores compared with those without infection (52.1±22.5 vs. 57.9±24.4, pConclusions Prior COVID-19 infection is associated with reduced restorative sleep quality as measured by REST-Q scores, independent of multiple confounders. The association persists although is partly attenuated when adjusted for anxiety and depression. These findings suggest a potential long-term impact of COVID-19 on self-reported restorative sleep and highlight the need for mechanistic and interventional research to address post-COVID sleep impairment. Brief Significance Statement This study is the first to examine the association between prior COVID-19 infection and restorative sleep using the validated Restorative Sleep Questionnaire (REST-Q) in a large, nationally representative U.S. sample. Findings demonstrate that individuals with a history of COVID-19 report significantly poorer restorative sleep, independent of multiple demographic, socioeconomic, and sleep-related factors, underscoring the need for targeted post-COVID sleep interventions.
Open AccessAssociation of Prior COVID-19 Infection with Restorative Sleep Quality Using REST-Q Scores: Findings from the COPE Initiative
Objectives The COVID-19 pandemic has disrupted sleep health globally. However, the relationship between prior SARS-CoV-2 infection and subjective restorative sleep, measured using validated instruments, remains underexplored. This study evaluated the association between prior SARS-CoV-2 infection and restorative sleep quality using Restorative Sleep Questionnaire (REST-Q) scores in a large, nationally representative U.S. sample. Methods Data were obtained from the September–October 2022 wave of the COVID-19 Outbreak Public Evaluation (COPE) Initiative, a cross-sectional online survey of 4,982 adults approximating the U.S. population by age, sex, race, and ethnicity. Restorative sleep was measured using the 9-item REST-Q. COVID-19 infection status was self-reported and categorized as never infected, one infection, or ≥ 2 infections. General linear models and ordinal logistic regression assessed associations between infection status and REST-Q scores, adjusting for demographic, socioeconomic, comorbidity, sleep-related, and mental health variables (Patient Health Questionnaire-4). Results Participants with prior COVID-19 infection had significantly lower REST-Q scores compared with those without infection (52.1±22.5 vs. 57.9±24.4, pConclusions Prior COVID-19 infection is associated with reduced restorative sleep quality as measured by REST-Q scores, independent of multiple confounders. The association persists although is partly attenuated when adjusted for anxiety and depression. These findings suggest a potential long-term impact of COVID-19 on self-reported restorative sleep and highlight the need for mechanistic and interventional research to address post-COVID sleep impairment. Brief Significance Statement This study is the first to examine the association between prior COVID-19 infection and restorative sleep using the validated Restorative Sleep Questionnaire (REST-Q) in a large, nationally representative U.S. sample. Findings demonstrate that individuals with a history of COVID-19 report significantly poorer restorative sleep, independent of multiple demographic, socioeconomic, and sleep-related factors, underscoring the need for targeted post-COVID sleep interventions.
- 25 June 2025
- Published by Springer Nature in Sleep and Breathing
- Vol. 29 (4) , 1-7
Obstructive sleep apnea is a risk factor for incident COVID-19 infection
- 25 June 2025
- Published by Springer Nature in Sleep and Breathing
- Vol. 29 (4) , 1-7
Obstructive sleep apnea is a risk factor for incident COVID-19 infection